The AAPS Annual Meeting and Exposition showcases late-breaking research, validates scientific methodology, and reveals the latest technology, services, and supplies. Speakers include scientists from the Food and Drug Administration, National Institute of Health, leading pharmaceutical companies, and academia.
Mark your calendar for the meeting that extends your boundaries.
Widen your personal network with scientists from all fields related to pharmaceutical sciences.
Explore programming covering both large and small pharma.
Find the latest advances with over 2,500 contributed papers.
Exhibit at the AAPS Annual Meeting and Exposition and reach the most concentrated audience of pharmaceutical scientists in the world.
Maximize your time and marketing dollars while receiving immediate feedback on new products and services. In one location, you can close sales on the spot, answer the questions that lead to future sales, schedule follow-up meetings and sales calls, and learn what information and services pharmaceutical scientists-your valuable prospects-will need to finalize purchasing decisions.
About the Exposition
The AAPS Annual Meeting and Exposition is the "must attend" event in the pharmaceutical science industry.
Our attendees are involved in all phases of drug development, which include:
pharmaceutical development (dosage form design),
management of research and development,
pharmaceutical analytical development,
biopharmaceutics and pharmacokinetics,
technology transfer/technical services,
drug delivery research,
quality assurance/quality control,
and much more.
The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 10,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health.
New and Upcoming Drug Modalities
Regulatory Considerations into the Translational Aspects and Preclinical Evaluation of Immuno-oncology Drugs
Wyss Institute at Harvard University
Donald E. Ingber, M.D., Ph.D., is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences. He received his B.A., M.A., M.Phil., M.D. and Ph.D. from Yale University.
Ingber is a pioneer in the field of biologically inspired engineering, and at the Wyss Institute, he currently leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art and design.
Ingber has authored more than 430 publications and 150 patents, founded 5 companies, and has presented 517 plenary presentations and invited lectures world-wide. He is a member of the National Academy of Medicine, National Academy of Inventors, American Institute for Medical and Biological Engineering, and the American Academy of Arts and Sciences. He was named one of the Top 20 Translational Researchers world-wide in 2012 (Nature Biotechnology), a Leading Global Thinker of 2015 (Foreign Policy magazine), and has received numerous other honors in a broad range of disciplines, including the Robert A. Pritzker Award and the Shu Chien Award (Biomedical Engineering Society), the Rous Whipple Award (American Society for Investigative Pathology), the Lifetime Achievement Award (Society of In Vitro Biology), the Leading Edge Award (Society of Toxicology), Founders Award (Biophysical Society) and the Department of Defense Breast Cancer Innovator Award.
Some of Ingber’s most recently developed technologies include an anticoagulant surface coating for medical devices that replaces the need for dangerous blood-thinning drugs; a dialysis-like sepsis therapeutic device that clears blood of pathogens and inflammatory toxins; a shear stress-activated nanotherapeutic that targets clot-busting drugs to sites of vascular occlusion; and Human Organs-on-Chips created with microchip manufacturing methods and lined by living human cells, which are being used to replace animal testing as a more accurate and affordable in vitro platform for drug development and personalized medicine. In 2015, Ingber’s Organs-on-Chips technology was named Design of the Year by the London Design Museum and was also acquired by the Museum of Modern Art (MoMA) in New York City for its permanent design collection. His Organs-on-Chips were also named one of the Top 10 Emerging Technologies of 2016 by the World Economic Forum.